# Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease

> **NCT00329160** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 214 (actual)

## Conditions studied

- Hypercholesteremia

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** HMG CoA inhibitor

## Key facts

- **NCT ID:** NCT00329160
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2011-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329160, "Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00329160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*